New Diagnostics for Gliomas


ConsulTech at BioEurope 2019 in Hamburg

Coordinator ConsulTech will participate at the partnering activities of BioEurope 2019, the largest event of this kind in Europe (see Login into your partnering account here and get in touch with us.
We are spinning out a new company in which we will transfer all the assets of the project. The company will be incorporated in November and will be named ALBEGA Medical. We have set-up a preliminary homepage here.

Gliomark in short movie of a parlamentary Group of the European Parliament

The Group of Progressive Alliance of Socialists and Democrats in the European Parliament included Gliomark in a video for the use of EU funding into innovative projects. Read Moreā€¦

GLIOMARK consortium at EIT Innovators summit 2018 in Berlin

The Greek-German GLIOMARK consortium will be present at the EIT Innovator´s Summit, taking place in Berlin on 10th-11th September, 2018. With Athens-based ProActina SA and Berlin-based ConsulTech GmbH two small and medium-sized companies (SMEs) have been cooperating intensively for three years now in the development of a diagnostic agent for rare high-grade brain tumors (gliomas). Now, the first clinical success of this Greek-German collaboration can be announced: the clinical study Gliomark1 (phase II) has been successfully completed.
At EIT innovator´s summit will take part around 1000 top innovators, investors and corporates. They will gather for hands-on workshops, relevant matchmaking, a showcase by European top innovators and inspiring talks. Dr. Alexandros Strongilos (CEO of ProActina) and Dr. Daniel Schubart (CEO of ConsulTech) will take this opportunity to meet peers, pitch the project, present their ideas in front of top investors, exchange experiences and find new partnerships.

GLIOMARK1 clinical study successfully completed

The GLIOMARK consortium is delighted to announce that the Gliomark1 Phase II clinical study has been successfully completed.

Gliomark1: Phase II exploratory study assessing the technical performance of 99mTc-tetrofosmin for the differentiation of tumour recurrence vs. radiation-necrosis in patients with high grade brain tumours following initial treatment (EudraCT No.: 2015-005573-21, ID: NCT02971319).

The study, conducted in 6 large glioma centers in Europe, met all end-points, regarding both technical and diagnostic performance of 99mTc-tetrofosmin, and sets a strong basis for the design of a successful phase III confirmatory study.

The Consortium wishes to thank all the Principal Investigators and their dedicated teams, as well as our highly experienced team of Medical Advisors for their impactful contribution and commitment to bringing the study to its successful completion.

Dr Alex Strongilos, CEO of proACTINA, stated that “the successful completion of the phase II study is a major advancement towards the completion of this ambitious project and it constitutes a very strong foundation for the upcoming Phase III study”.

Dr Daniel Schubart, Managing Director of ConsulTech, stated that “We have now reached a very important milestone of the GLIOMARK project and we are very enthusiastic about this significant achievement”.

GLIOMARK at BIO-Europe in Berlin (November 6th-8th)

The GLIOMAKR consortium will be present at the BIO-Europe, which takes place in Berlin between 6th - 8th November 2017!
BIO-Europe is Europe’s biggest pharma and biotechnology partnering conference, bringing together decision makers from life science and the investors. The accompanying exhibition is an unmissable opportunity to meet new customers, and to present innovative ideas and projects to VC, customers and partners.
Meet us using the partnering tool of the conference and discuss opportunities for cooperation!

GLIOMARK consortium member Pro-Actina selected as SME instrument ambassador

Pro-ACTINA is proud to participate in the BIO International Convention in San Diego, selected as one of the 15 European SMEs Instrument Ambassadors under the EASME Overseas Trade Fairs program aiming to support international commercialization of EU innovation. From 19-22 June 2017, pro-ACTINA will have the unique opportunity to gain first-hand experience of the US market and establish business contacts with local companies via the trade fair and business meetings.
Visit us at booth #5837!

Meet us at BioEUROPE in Cologne

The consortium will participate in Europe's largest partnering conference serving the global biotechnology industry, the BIO-Europe.
You may approach us through the partnering system of the conference. We look forward to discussing cooperations with you.

Orphan designation for Tetrofosmin

The consortium is pleased to announce that, on 14/10/2016 the European Commission has granted to proACTINA SA, Orphan Designation for tetrofosmin for the diagnosis of Glioma, following positive opinion by EMA. The product is registered in the “Community register of orphan medicinal products” with an EU orphan designation number: EU/3/16/1764.

This achievement has been one of the major milestones in GLIOMARK project.

See here the related press release.

Gliomark presenting at MEDICA, the world's leading trade fair for the medical industry

Visit us at the MEDICA in Düsseldorf, Germany!
We will be found in hall 3 booth G60 under the umbrella of the Berlin Diagnostic Net booth.
MEDICA is the world’s leading medical trade fair with more than 4,900 exhibitors and 130,000 visitors and is taking place from 14 - 17 November 2016.

Article about Gliomark in Science Business

Gliomark is subject of a recently published article in Science | Business, a web site and service aiming at bringing together research, industry and policy. The article is found here.

Announcement of GLIOMARK by the Greek National Documentation Center

Our project has been published in National Documentation Center’s bi-monthly newsletter for research and Innovation. Please find this publication here.

Presentation of GLIOMARK

pro-Actina's CEO, Alexandros Strongilos, was invited to present the Gliomark project on Nov 3, 2015 in frame of a Horizon 2020 dedicated event organized by the Greek National Contact point.

20151103_hmerida  - 0148

Please see the agenda and the presentation as well as a video of the presentation (in Greek).

Project GLIOMARK has started

The European Commission, within the frames of Horizon 2020-SME-Instrument-Phase 2 (PHC-12), has positively evaluated the project "GLIOMARK" and approved funding of €4.7 million for the next 4 years. Objective of "GLIOMARK" is to clinically validate the permeability of the blood brain barrier (BBB) as an in vivo biomarker for the diagnosis of gliomas. This will be accomplished by means of the radiotracer 99mTc-tetrofosmin (TTF) and the imaging technique Single-Photon Emission Computer Tomography (SPECT). The project will be coordinated by ConsulTech GmbH (Germany) and implemented in close collaboration with ProActina SA (Greece).